Glaukos Q1 2025 net sales rise 25% to $106.7 million; 2025 guidance reaffirmed
Glaukos reported first quarter 2025 results on April 30, 2025, with net sales of $106.7 million, up 25% from $85.6 million a year earlier. The net loss narrowed to $18.1 million, or $0.32 per diluted share, from $40.8 million, or $0.82 per share, in the first quarter of 2024. The company reaffirmed its 2025 net sales guidance of $475 million to $485 million.
Key points
- Q1 2025 net sales were $106.7 million, up 25% reported and 26% on a constant currency basis.
- U.S. Glaucoma net sales were $59.1 million, up 41%, driven by iDose TR.
- Net loss was $18.1 million, or $0.32 per diluted share, versus $40.8 million, or $0.82 per share, a year earlier.
- The company ended the first quarter with about $303.4 million in cash, short-term investments and restricted cash, and no debt.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:12 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 30, 2025.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.